



Announcement Summary

Entity name

NOVA EYE MEDICAL LIMITED

Announcement Type

New announcement

Date of this announcement

Monday May 05, 2025

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Consideration provided under a consulting agreement in America including

- 1.1. Clinical marketing and development and publication and presentation of data
- 1.2. New product development
- 1.3. Peer-to-peer education
- 1.4. Clinical investigation

The agreement is hourly rate for work performed

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
EYE	ORDINARY FULLY PAID	45,236	06/05/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

NOVA EYE MEDICAL LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ABN

Registration number

15007702927

1.3 ASX issuer code

EYE

1.4 The announcement is

New announcement

1.5 Date of this announcement

5/5/2025

For personal use only



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Consideration provided under a consulting agreement in America including

- 1.1. Clinical marketing and development and publication and presentation of data
- 1.2. New product development
- 1.3. Peer-to-peer education
- 1.4. Clinical investigation

The agreement is hourly rate for work performed

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

EYE : ORDINARY FULLY PAID

Issue date

6/5/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

45,236

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Services provided under a consulting agreement

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.160000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

To pay for services rendered

Please provide additional details

Services provided under a consulting agreement including

- 1.1. Clinical marketing and development and publication and presentation of data
- 1.2. New product development , take part in medical advisory discussions, testing and evaluation
- 1.3. Peer-to-peer education , host and/or participate in various initiatives, including surgical observation and physician proctoring
- 1.4. Clinical investigation , take part in clinical investigations for existing and new technologies



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
EYE : ORDINARY FULLY PAID	284,125,000

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
EYEAD : OPTION EXPIRING 31-MAY-2024 EX \$0.50	260,000
EYEAH : OPTION EXPIRING 31-JUL-2025 EX \$0.35	100,000
EYEAC : PERFORMANCE RIGHTS	788,347
EYEAG : OPTION EXPIRING 13-MAY-2025 EX \$0.282	400,000
EYEAI : OPTION EXPIRING 13-JUL-2026 EX \$0.35	100,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

45,236

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No

For personal use only